Compound reference
P21
Also known as CNTF-derived P21
P21 (also written P021) is a small CNTF-derived neurotrophic peptide that boosts hippocampal neurogenesis and synaptic plasticity. Its Alzheimer's-model data are strong and consistent — but they come from essentially one research group, and there are no human trials.
- Sequence
- Ac-DGGLAG-NH₂ — an adamantane-modified peptide from the active region of CNTF (~residues 146-156)
Research peptide; not FDA-approved as a drug.
Mode of action
P21 (also written P021) is a small, rationally designed peptidergic compound derived from the biologically active region of ciliary neurotrophic factor (CNTF). Its core is the short acetylated/amidated sequence Ac-DGGLAG-NH₂, carrying an adamantane modification that increases lipophilicity, improves blood-brain-barrier penetration, and resists exopeptidase degradation — engineering meant to capture CNTF's neurotrophic activity without the poor pharmacokinetics and side effects of the full protein.
Functionally it acts as a neurotrophic and neurogenic agent: it stimulates neurogenesis in the hippocampal dentate gyrus, enhances dendritic and synaptic complexity, increases BDNF, and relieves the suppression of neurogenesis mediated by leukemia inhibitory factor signaling. The result, in animal models, is improved neuroplasticity and cognition. It was developed by Khalid Iqbal's group at the New York State Institute for Basic Research.
Main intended effect
To restore neuroplasticity — driving neurogenesis and synaptic repair — and thereby improve cognition, principally as a strategy against Alzheimer's disease.
Areas of interest
The central interest is Alzheimer's disease and related neurodegeneration, with additional work in neurodevelopmental models. In the consumer market P21 is sold as a neurogenic "nootropic" research peptide.
Evidence for intended effects
The preclinical evidence is genuinely strong and internally consistent. In the 3xTg model of Alzheimer's disease, P021 reversed neurogenic and neuroplastic deficits and cognitive impairment; adamantane-modified neurotrophic peptides improved learning, memory, neurogenesis, and synaptic plasticity in mice; and early postnatal treatment prevented later Alzheimer-like behavioral and synaptic dysfunction. Review syntheses (including an Alzheimer's Drug Discovery Foundation evidence report) treat it as a promising neurotrophic-mimetic candidate.
The limitation is the familiar one for compounds at this stage. Almost all of this work originates from a single research group, and there are no clinical trials in humans — the cognitive and neurogenic benefits have not been tested in people. So P21 is a well-characterized, mechanistically attractive preclinical candidate, not a demonstrated treatment.
| Strand | What exists | Tier |
|---|---|---|
| Alzheimer's models | Neurogenesis, synaptic, cognitive rescue in transgenic mice | Strong preclinical |
| Mechanism | CNTF mimetic; neurogenesis, BDNF, anti-LIF signaling | Well characterized |
| Single-group / replication | Predominantly one research network | Limited independence |
| Human | None | No trials |
Studied amounts (literature dosing context)
The animal studies dosed P021 peripherally (including oral and injected routes) over weeks to months in mouse models. There is no established human dose. These are preclinical figures, and this page does not provide dosing guidance.
Safety and regulatory status
There is no human safety data for P21, because there have been no human studies. It is not an approved drug in any jurisdiction; it is sold as a research peptide for cognition and neuroprotection, where product identity and purity are not assured. Mechanistically it is in the same procognitive/neurotrophic space as Dihexa, another small molecule pursued for the same Alzheimer's-related goals on a preclinical-only evidence base.
Sources
Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Abeta and tau pathologies in 3xTg-AD mice
Blanchard and colleagues administered Peptide 6 (P021), an 11-amino-acid fragment corresponding to the active region of ciliary neurotrophic factor (CNTF residues 146–156), peripherally to 9-month-old 3xTg-AD mice modeling Alzheimer's disease. Treatment enhanced neurogenesis in the dentate gyrus, reduced ectopic neuronal birth in the granular cell layer, and increased synaptic plasticity markers in the hippocampus and cerebral cortex, with concomitant restoration of cognitive performance. Critically, these improvements occurred without detectable reductions in amyloid-beta or tau pathology, suggesting a neuroregeneration mechanism independent of hallmark lesion clearance. These are mouse model findings; the peptide has not been tested in human clinical trials.
Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice
Li and colleagues studied P21 (Ac-DGGLAG-NH2), an adamantane-modified hexapeptide derived from the CNTF active region, administered peripherally in adult C57BL/6 mice. P21 enhanced acquisition of learning and both short-term and spatial reference memory tasks, promoted neurogenesis in the dentate gyrus, and induced maturation of newly born neurons in the granular cell layer and subgranular zone. The adamantane modification was designed to improve metabolic stability and facilitate blood-brain barrier penetration compared to the unmodified peptide. The authors proposed P21 as a candidate for neurodegenerative conditions including Alzheimer's disease, though all findings are from a mouse model and no human safety or efficacy data are available.
Neurotrophic treatment initiated during early postnatal development prevents the Alzheimer-like behavior and synaptic dysfunction
Preclinical study in a transgenic Alzheimer's disease mouse model (Journal of Alzheimer's Disease, 2021) examining whether early postnatal intervention with P021, a CNTF-derived neurotrophic peptide, could prevent the emergence of Alzheimer-like pathology. Treatment initiated during the early postnatal period was associated with prevention of Alzheimer-like behavioral deficits and synaptic dysfunction later in life. The proposed mechanism involves neurotrophic support during a critical developmental window when synaptic compensation is still possible, consistent with the related Blanchard et al. 2010 work showing neurogenesis and plasticity improvement independent of amyloid-beta or tau clearance. All findings are from a rodent model and do not constitute human clinical evidence.
Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease
Review by Kazim and Iqbal (Mol Neurodegener, 2016) evaluating small-molecule and peptide mimetics of neurotrophic factors as therapeutic candidates for Alzheimer's disease, with detailed focus on P021, a CNTF-derived tetrapeptide. The authors describe P021's mechanism of action: it enhances dentate gyrus neurogenesis and memory processes by inhibiting the LIF signalling pathway and increasing BDNF expression, and robustly suppresses tau hyperphosphorylation through BDNF-mediated reduction of GSK-3β activity. Preclinical studies in 3xTg-AD mice showed reductions in tau pathology, enhanced neurogenesis, and rescued dendritic and synaptic loss. P021 is noted to be blood-brain-barrier permeable and orally bioavailable with a favourable safety profile compared to recombinant CNTF. The authors identify it as a highly promising disease-modifying candidate but note that human clinical evidence was absent at time of publication.
Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound
Review published in Biomolecules (2022) examining Alzheimer's disease pathogenesis and the therapeutic rationale for neurotrophic peptide strategies, with particular focus on P021, a tetrapeptide derived from CNTF. The authors contextualise P021 within the cholinergic and neurotrophic deficit hypotheses of AD, describing preclinical evidence for its capacity to stimulate hippocampal neurogenesis, reduce pathological tau hyperphosphorylation via GSK-3β inhibition, and enhance synaptic plasticity in transgenic AD mouse models. The review compares P021 favourably to native CNTF with respect to CNS penetration, molecular weight, and tolerability. The authors acknowledge that Alzheimer's disease polypathology complicates single-target approaches and that human efficacy trials for P021 had not been completed, limiting clinical conclusions.
Cognitive Vitality Report: P021
Evidence evaluation produced by the Alzheimer's Drug Discovery Foundation (Cognitive Vitality series, 2025) examining P021, a small-molecule peptide mimetic derived from ciliary neurotrophic factor (CNTF). The report summarises preclinical mechanistic evidence that P021 enhances hippocampal neurogenesis and BDNF expression, inhibits GSK-3β to reduce tau hyperphosphorylation, and rescues dendritic and synaptic deficits in transgenic Alzheimer's mouse models. Key pharmacological properties noted include blood-brain-barrier permeability, low molecular weight, and an absence of the adverse effects associated with recombinant CNTF protein. The ADDF concludes that no human clinical efficacy data exist for P021, characterising it as a preclinically promising but clinically unvalidated compound. The report is an evidence-grading exercise and not a primary study.
https://www.alzdiscovery.org/uploads/cognitive_vitality_media/P021.pdf